These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1208 related articles for article (PubMed ID: 33262189)

  • 1. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
    Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
    BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acupuncture and Escitalopram for Treating Major Depression Clinical Study (AE-TMDCS): protocol for a factorial randomised controlled trial.
    Yang K; Tiwari S; Liu D; Xu Q; Qi L; Zhu Y; Jiang L; Zouqin H; Wong J; Chen J; Han Z
    BMJ Open; 2024 Sep; 14(9):e091214. PubMed ID: 39260834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
    Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
    Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Salagre E; Fernandes BS; Dodd S; Brownstein DJ; Berk M
    J Affect Disord; 2016 Aug; 200():235-42. PubMed ID: 27148902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
    McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
    Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol.
    Maji S; Mohapatra D; Jena M; Srinivasan A; Maiti R
    BMJ Open; 2024 Apr; 14(4):e080500. PubMed ID: 38688675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
    Moore N; Verdoux H; Fantino B
    Int Clin Psychopharmacol; 2005 May; 20(3):131-7. PubMed ID: 15812262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
    Lepola U; Wade A; Andersen HF
    Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.